Transparency Bill Includes Measure Aimed At Speeding Up Generics

By Jessica Karins / December 12, 2023 at 12:08 PM
The Lower Costs, More Transparency Act passed by the House with a bipartisan majority Monday (Dec. 11) includes a provision requiring FDA to share more information with sponsors about its findings on whether generic drugs are equivalent to reference products -- a measure aimed at speeding up the process for bringing generics to market. The bill is intended to streamline approvals of generic drugs, allowing for more price competition with higher-cost reference products. However, the move comes amid criticism from...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.